MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response

MFSD2A potentiates gastric cancer response to anti‐PD‐1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response

Abstract Background The efficacy of anti‐programmed cell death protein 1 (PD‐1) immunotherapy in various cancers, including gastric cancer (GC), needs to be potentiated by more effective targeting to enhance therapeutic efficacy or identifying accurate biomarkers to predict clinical responses. Here,...

Full description

Bibliographic Details
Main Authors: Bin Zhang, Chun‐Mei Wang, Hao‐Xiang Wu, Feng Wang, Yang‐Yang Chai, Ye Hu, Bing‐Jing Wang, Zhou Yu, Rong‐Hua Xia, Rui‐Hua Xu, Xue‐Tao Cao
Format: Article
Language:English
Published: Wiley 2023-10-01
Series:Cancer Communications
Subjects:
MFSD2A
immunotherapy
anti‐PD‐1
gastric cancer
TME
T cell activation
Online Access:https://doi.org/10.1002/cac2.12476

Similar Items

Similar Items